Login to Your Account



Seeing the Forest for Trevena: $30M, Option for Heart Drug

By Randy Osborne
Staff Writer

Thursday, May 9, 2013
revena Inc.'s deal with a subsidiary of Forest Laboratories Inc. brings a $30 million equity investment in exchange for an option to license worldwide rights to TRV027, an angiotensin II Type I receptor biased ligand for acute decompensated heart failure, after results are clear from a 500-patient Phase IIb trial, slated to begin by the end of the year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription